What was the market valuation for the Respiratory Infectious Disease Diagnostics Market in 2024?

The market valuation for the Respiratory Infectious Disease Diagnostics Market in 2024 was 4.305 USD Billion. Read More

What is the expected CAGR for the Respiratory Infectious Disease Diagnostics Market from 2025 to 2035?

The expected CAGR for the Respiratory Infectious Disease Diagnostics Market during the forecast period 2025 - 2035 is 4.23%. Read More

Which technology segment is projected to have the highest valuation in 2035?

The Molecular Diagnostics segment is projected to reach 2.4 USD Billion in 2035, indicating strong growth. Read More

What are the projected valuations for the sample type segment in 2035?

In 2035, the projected valuations for the sample type segment include Nasopharyngeal Swabs at 1.35 USD Billion and Sputum at 1.05 USD Billion. Read More

Which infectious agent segment is expected to show the most growth by 2035?

The Viruses segment is expected to show the most growth, with a projected valuation of 2.7 USD Billion in 2035. Read More

What is the anticipated market performance for hospitals and clinics in 2035?

The hospitals and clinics segment is anticipated to reach a valuation of 2.4 USD Billion in 2035, reflecting robust demand. Read More

How do the key players influence the Respiratory Infectious Disease Diagnostics Market?

Key players like Roche, Abbott, and Thermo Fisher Scientific are likely to drive innovation and market growth through advanced diagnostic solutions. Read More

What is the projected valuation for point-of-care settings in 2035?

The projected valuation for point-of-care settings in 2035 is 1.4 USD Billion, indicating a growing trend in accessible diagnostics. Read More

What is the expected growth trend for the culture-based diagnostics segment by 2035?

The culture-based diagnostics segment is expected to grow modestly, with a projected valuation of 0.4 USD Billion in 2035. Read More

Respiratory Infectious Disease Diagnostics Market

Q: What is the projected market valuation for the Respiratory Infectious Disease Diagnostics Market in 2035?

The projected market valuation for the Respiratory Infectious Disease Diagnostics Market in 2035 is 6.79 USD Billion. Read More

Respiratory Infectious Disease Diagnostics Market Research Report: Size, Share, Trend Analysis By Technology (Molecular Diagnostics, Immunoassays, Viral Load Assays, Microscopy, Culture-Based Diagnostics), By Sample Type (Nasopharyngeal Swabs, Oropharyngeal Swabs, Sputum, Blood, Urine), By Infectious Agent (Bacteria, Viruses, Fungus, Parasites), By End Use (Hospitals and Clinics, Laboratories, Point-of-Care Settings, Home Use) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.23%

2024 Market Size

$ 4.3 Billion

2035 Market Size

$ 6.79 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/39137-HCR | Pages: 128 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Technology (USD Billion)
  1. 4.1.1 Molecular Diagnostics
  2. 4.1.2 Immunoassays
  3. 4.1.3 Viral Load Assays
  4. 4.1.4 Microscopy
  5. 4.1.5 Culture-Based Diagnostics
2. 4.2 Healthcare, BY Sample Type (USD Billion)
  1. 4.2.1 Nasopharyngeal Swabs
  2. 4.2.2 Oropharyngeal Swabs
  3. 4.2.3 Sputum
  4. 4.2.4 Blood
  5. 4.2.5 Urine
3. 4.3 Healthcare, BY Infectious Agent (USD Billion)
  1. 4.3.1 Bacteria
  2. 4.3.2 Viruses
  3. 4.3.3 Fungus
  4. 4.3.4 Parasites
4. 4.4 Healthcare, BY End-Use (USD Billion)
  1. 4.4.1 Hospitals and Clinics
  2. 4.4.2 Laboratories
  3. 4.4.3 Point-of-Care Settings
  4. 4.4.4 Home Use
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Siemens Healthineers (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 BD (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 bioMerieux (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Cepheid (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Hologic (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 QuidelOrtho (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
4. 6.4 US MARKET ANALYSIS BY SAMPLE TYPE
5. 6.5 US MARKET ANALYSIS BY INFECTIOUS AGENT
6. 6.6 US MARKET ANALYSIS BY END-USE
7. 6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY
8. 6.8 CANADA MARKET ANALYSIS BY SAMPLE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY INFECTIOUS AGENT
10. 6.10 CANADA MARKET ANALYSIS BY END-USE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY
13. 6.13 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY INFECTIOUS AGENT
15. 6.15 GERMANY MARKET ANALYSIS BY END-USE
16. 6.16 UK MARKET ANALYSIS BY TECHNOLOGY
17. 6.17 UK MARKET ANALYSIS BY SAMPLE TYPE
18. 6.18 UK MARKET ANALYSIS BY INFECTIOUS AGENT
19. 6.19 UK MARKET ANALYSIS BY END-USE
20. 6.20 FRANCE MARKET ANALYSIS BY TECHNOLOGY
21. 6.21 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY INFECTIOUS AGENT
23. 6.23 FRANCE MARKET ANALYSIS BY END-USE
24. 6.24 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
25. 6.25 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY INFECTIOUS AGENT
27. 6.27 RUSSIA MARKET ANALYSIS BY END-USE
28. 6.28 ITALY MARKET ANALYSIS BY TECHNOLOGY
29. 6.29 ITALY MARKET ANALYSIS BY SAMPLE TYPE
30. 6.30 ITALY MARKET ANALYSIS BY INFECTIOUS AGENT
31. 6.31 ITALY MARKET ANALYSIS BY END-USE
32. 6.32 SPAIN MARKET ANALYSIS BY TECHNOLOGY
33. 6.33 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY INFECTIOUS AGENT
35. 6.35 SPAIN MARKET ANALYSIS BY END-USE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY INFECTIOUS AGENT
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TECHNOLOGY
42. 6.42 CHINA MARKET ANALYSIS BY SAMPLE TYPE
43. 6.43 CHINA MARKET ANALYSIS BY INFECTIOUS AGENT
44. 6.44 CHINA MARKET ANALYSIS BY END-USE
45. 6.45 INDIA MARKET ANALYSIS BY TECHNOLOGY
46. 6.46 INDIA MARKET ANALYSIS BY SAMPLE TYPE
47. 6.47 INDIA MARKET ANALYSIS BY INFECTIOUS AGENT
48. 6.48 INDIA MARKET ANALYSIS BY END-USE
49. 6.49 JAPAN MARKET ANALYSIS BY TECHNOLOGY
50. 6.50 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY INFECTIOUS AGENT
52. 6.52 JAPAN MARKET ANALYSIS BY END-USE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY INFECTIOUS AGENT
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USE
57. 6.57 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
58. 6.58 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY INFECTIOUS AGENT
60. 6.60 MALAYSIA MARKET ANALYSIS BY END-USE
61. 6.61 THAILAND MARKET ANALYSIS BY TECHNOLOGY
62. 6.62 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY INFECTIOUS AGENT
64. 6.64 THAILAND MARKET ANALYSIS BY END-USE
65. 6.65 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
66. 6.66 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY INFECTIOUS AGENT
68. 6.68 INDONESIA MARKET ANALYSIS BY END-USE
69. 6.69 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
70. 6.70 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY INFECTIOUS AGENT
72. 6.72 REST OF APAC MARKET ANALYSIS BY END-USE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
75. 6.75 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY INFECTIOUS AGENT
77. 6.77 BRAZIL MARKET ANALYSIS BY END-USE
78. 6.78 MEXICO MARKET ANALYSIS BY TECHNOLOGY
79. 6.79 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY INFECTIOUS AGENT
81. 6.81 MEXICO MARKET ANALYSIS BY END-USE
82. 6.82 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
83. 6.83 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY INFECTIOUS AGENT
85. 6.85 ARGENTINA MARKET ANALYSIS BY END-USE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INFECTIOUS AGENT
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INFECTIOUS AGENT
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INFECTIOUS AGENT
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USE
99. 6.99 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
100. 6.100 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY INFECTIOUS AGENT
102. 6.102 REST OF MEA MARKET ANALYSIS BY END-USE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY INFECTIOUS AGENT, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY INFECTIOUS AGENT, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END-USE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.2.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.2.4 BY END-USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.3.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.3.4 BY END-USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.4.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.4.4 BY END-USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.5.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.5.4 BY END-USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.6.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.6.4 BY END-USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.7.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.7.4 BY END-USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.8.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.8.4 BY END-USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.9.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.9.4 BY END-USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.10.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.10.4 BY END-USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.11.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.11.4 BY END-USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.12.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.12.4 BY END-USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.13.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.13.4 BY END-USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.14.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.14.4 BY END-USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.15.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.15.4 BY END-USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.16.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.16.4 BY END-USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.17.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.17.4 BY END-USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.18.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.18.4 BY END-USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.19.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.19.4 BY END-USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.20.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.20.4 BY END-USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.21.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.21.4 BY END-USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.22.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.22.4 BY END-USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.23.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.23.4 BY END-USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.24.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.24.4 BY END-USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.25.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.25.4 BY END-USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.26.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.26.4 BY END-USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.27.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.27.4 BY END-USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.28.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.28.4 BY END-USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.29.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.29.4 BY END-USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  2. 7.30.2 BY SAMPLE TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY INFECTIOUS AGENT, 2025-2035 (USD Billion)
  4. 7.30.4 BY END-USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Respiratory Infectious Disease Diagnostics Market Segmentation

Respiratory Infectious Disease Diagnostics Market By Respiratory Infectious Disease Diagnostics Market (USD Billion, 2025-2035)

Molecular Diagnostics
Immunoassays
Viral Load Assays
Microscopy
Culture-Based Diagnostics

Respiratory Infectious Disease Diagnostics Market By Sample Type (USD Billion, 2025-2035)

Nasopharyngeal Swabs
Oropharyngeal Swabs
Sputum
Blood
Urine

Respiratory Infectious Disease Diagnostics Market By Infectious Agent (USD Billion, 2025-2035)

Bacteria
Viruses
Fungus
Parasites

Respiratory Infectious Disease Diagnostics Market By End-Use (USD Billion, 2025-2035)

Hospitals and Clinics
Laboratories
Point-of-Care Settings
Home Use

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035